Supportive and Preventive Medicine
practice guideline. BMJ. 2020;368:l6722. https://doi.
org/10.1136/bmj.l6722
Prophylaxis Against Deep Venous Thrombosis or
Pulmonary Embolism
Arabi YM, Al-Hameed F, Burns KEA, et al. Adjunctive
intermittent pneumatic compression for venous throm-
boprophylaxis. N Engl J Med. 2019;380(14):1305-1315.
https://doi.org/10.1056/nejmoa1816150
Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS,
Geerts WH. Deep vein thrombosis and its prevention in
critically ill adults. Arch Intern Med. 2001;161(10):1268-
1279. https://doi.org/10.1001/archinte.161.10.1268
Beiderlinden M, Treschan TA, Görlinger K, Peters J.
Argatroban anticoagulation in critically ill patients.
org/10.1345/aph.1h569
Cade JF. High risk of the critically ill for venous throm-
doi.org/10.1097/00003246-198207000-00006
Chi G, Gibson CM, Kalayci A, et al. Extended-duration
betrixaban versus shorter-duration enoxaparin for
venous thromboembolism prophylaxis in critically ill
medical patients: an APEX trial substudy. Intensive
s00134-019-05565-6
Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for
thromboprophylaxis in acutely ill medical patients. N
Engl J Med. 2013;368(6):513-523. https://doi.org/10.1056/
nejmoa1111096
Cook D, Crowther M, Meade M, et al. Deep venous
thrombosis in medical-surgical critically ill patients:
Med. 2005;33(7):1565-1571. https://doi.org/10.1097/01.
ccm.0000171207.95319.b2
Cook D, Meade M, Guyatt G, et al. Dalteparin versus unfrac-
tionated heparin in critically ill patients. N Engl J Med.
2011;364:1305-1314. https://doi.org/10.1056/nejmoa1014475
Cuker A, Arepally GM, Chong BH, et al. American
Society of Hematology 2018 guidelines for management
of venous thromboembolism: heparin-induced thrombo-
cytopenia. Blood Adv. 2018;2(22):3360-3392. https://doi.
org/10.1182/bloodadvances.2018024489
Cuker A, Gimotty PA, Crowther MA, Warkentin
TE. Predictive value of the 4Ts scoring system for
heparin-induced thrombocytopenia: a systematic review
and meta-analysis. Blood. 2012;120(20):4160-4167.
https://doi.org/10.1182/blood-2012-07-443051
De A, Roy P, Garg VK, Pandey NK. Low-molecular-
weight
heparin
and
unfractionated
heparin
in
prophylaxis against deep vein thrombosis in critically
ill patients undergoing major surgery. Blood Coagul
Fibrinolysis. 2010;21(1):57-61. https://doi.org/10.1097/
mbc.0b013e3283333505
Douketis J, Cook D, Meade M, et al. Prophylaxis
against deep vein thrombosis in critically ill patients
with severe renal insufficiency with the low-molecular-
weight heparin dalteparin: an assessment of safety and
pharmacodynamics: the DIRECT study. Arch Intern
Med. 2008;168(16):1805-1812. https://doi.org/10.1001/
archinte.168.16.1805
Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in
the prevention of deep vein thrombosis in acute decom-
pensated COPD. The Association of Non-University
https://doi.org/10.1164/ajrccm.161.4.9807025
Geerts W, Cook D, Selby R, Etchells E. Venous throm-
boembolism and its prevention in critical care. J
jcrc.2002.33941
Gould MK, Garcia DA, Wren SM, et al. Prevention of
VTE in nonorthopedic surgical patients: Antithrombotic
Therapy and Prevention of Thrombosis, 9th ed: American
College of Chest Physicians Evidence-Based Clinical
Practice Guidelines. Chest. 2012;141(2 suppl):e227S-
e277S. https://doi.org/10.1378/chest.11-2297
Joy M, Tharp E, Hartman H, et al. Safety and efficacy
of high-dose unfractionated heparin for prevention of
venous thromboembolism in overweight and obese
doi.org/10.1002/phar.1775
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE
in nonsurgical patients: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College
of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 suppl):e195S-e226S.
https://doi.org/10.1378/chest.11-2296
Kiser TH, Fish DN. Evaluation of bivalirudin
treatment for heparin-induced thrombocytopenia in crit-
ically ill patients with hepatic and/or renal dysfunction.